General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Bayer(SIGNIFICANT), stealth peptides(SIGNIFICANT), tricida(SIGNIFICANT), astra zeneca(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), Sanofi-Aventis(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), Forest Pharmaceuticals, Inc(SIGNIFICANT), scPharmaceuticals(SIGNIFICANT), KBP Biosciences(SIGNIFICANT), Juventas Therapeutics(SIGNIFICANT), Johnson & Johnson(SIGNIFICANT), novartis(SIGNIFICANT), Tenax Pharmaceuticals(SIGNIFICANT), Relypsa, Inc., a Vifor Pharma Group Company(SIGNIFICANT) OWNERSHIP/PARTNERSHIP/PRINCIPAL: scPharmaceuticals(SIGNIFICANT), Tricida(SIGNIFICANT), KBP Biosciences(SIGNIFICANT), AuraSense(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Juventas Therapeutics(SIGNIFICANT)

View Full Disclosure